Stephen De Rosa, MD
Research Associate Professor,
Laboratory Medicine, UW;
External Joint Associate Member, Vaccine and Infectious Disease Division, FHCRC;
Flow Vice Chair, Clinical Operations;
Flow Cytometry Laboratory Director, HIV Vaccine Trials Network
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. North, E4-200
Seattle, WA 98109-1024
Dr. De Rosa has worked with the HIV Vaccine Trials Network (HVTN) for the past eight years, and leads the flow cytometry laboratory. In this role, he oversees the operation and maintenance of the flow cytometer analyzers and sorters, directly supervises HVTN Research & Development technicians in the development and optimization of new flow cytometry-based assays, and consults with the Endpoints Laboratory manager concerning the performance and analysis of the validated flow cytometric assays conducted on clinical trial samples. Following graduation from medical school and some brief clinical training, he has pursued a full-time career in basic and applied research. He trained as a postdoctoral fellow in the Herzenberg Laboratory at Stanford, the laboratory that first developed flow cytometry technology 40 years ago. He then continued his training with Mario Roederer, an internationally-recognized flow expert, at the NIH Vaccine Research Center (VRC). While at the VRC, he implemented intracellular cytokine staining assays for evaluation of vaccine-induced T cells. He later implemented and validated similar assays within the HVTN. He is internationally recognized for this work in implementing and validating functional assays using cutting-edge technology for high throughput analysis of clinical trial samples.
Education and Training
- BS Chemical Engineering, Columbia University, New York, NY, 1983
- MD Stanford University School of Medicine, Stanford, CA, 1990
- Petiatric Intern, Stanford University Hospital, Stanford, CA, 1990-1991
- Pediatric Intern, Kaiser Permanente Hospital, San Francisco, CA, 1993-1994
- Postdoctoral Fellow, Stanford University School of Medicine, Stanford, CA, 1994-2000
- Research Fellow, Vaccine Research Center, NIH, Bethesda, MD, 2000-2004
- T-cell immunogenicity to candidate HIV vaccines
- Flow cytometric technology and data analysis
- Flow cytometric studies to evaluate cellular immunogenicity to HIV vaccines tested in the HIV Vaccine Trials Network Laboratory Program
- As director of the Immunology Core and director of the Flow Cytometry sub-Core of the University of Washington Center for AIDS Research (CFAR), provide assistance to investigators performing HIV-associated immunologic research.
- As an investigator in the Bill and Melinda Gates Foundtaion Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTVIMC), participate in standardization and validation of cellular assays and performance of assays to assess immunogenicity of novel HIV vaccines.
- Collaborator with L. Herzenberg at Stanford University for "Automated Comparison of Flow Data from HIV and Vaccine Infected Subjects" testing automated flow cytometric data analysis methods.
- Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., Liao, H. X., DeVico, A. L., Lewis, G. K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y., Rao, M., Billings, E., Karasavvas, N., Robb, M. L., Ngauy, V., de Souza, M. S., Paris, R., Ferrari, G., Bailer, R. T., Soderberg, K. A., Andrews, C., Berman, P. W., Frahm, N., De Rosa, S. C., Alpert, M. D., Yates, N. L., Shen, X., Koup, R. A., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N. L., and Kim, J. H. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366, 1275-1286.
- Gorse, G. J., Newman, M. J., Decamp, A., Hay, C. M., De Rosa, S. C., Noonan, E., Livingston, B. D., Fuchs, J. D., Kalams, S. A., and Cassis-Ghavami, F. L. (2012). DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-Lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-Uninfected, Vaccinia Virus-Naive Adults. Clin Vaccine Immunol 19, 649-658.
- Frahm, N., DeCamp, A. C., Friedrich, D. P., Carter, D. K., Defawe, O. D., Kublin, J. G., Casimiro, D. R., Duerr, A., Robertson, M. N., Buchbinder, S. P., Huang, Y., Spies, G. A., De Rosa, S. C., and McElrath, M. J. (2012). Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122, 359-367.
- Fong, Y., Wakefield, J., De Rosa, S. C., and Frahm, N. (2012). A Robust Bayesian Random Effects Model for Nonlinear Calibration Problems. Biometrics. 2012 Dec;68(4):1103-12.
- Defawe, O. D., Fong, Y., Vasilyeva, E., Pickett, M., Carter, D. K., Gabriel, E., Rerks-Ngarm, S., Nitayaphan, S., Frahm, N., McElrath, M. J., and De Rosa, S. C. (2012). Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells. J Immunol Methods. 2012 Aug 31;382(1-2):117-28.
Honors and Awards
- Immunology Program Training Grant, Postdoctoral Fellowship 5T32 AI-07290, 1995-1997
- American Cancer Society, PF-4469, Postdoctoral Fellowship, 1997
- University of California, Universitywide AIDS Research Program, Postdoctoral Fellowship F97-ST-044, 1997-1999 "Does thioredoxin play a role in neoplasia and death in AIDS?"
Last updated: 1/17/2013